Phase II Study of BEvacizumab in Combination with ATezolizumab in Patients with Untreated Melanoma Brain Metastases (BEAT-MBM).
The goal of this clinical research study is to learn if atezolizumab and bevacizumab can help to control the disease in patients with cancer that has spread to the brain. The safety of this drug combination will also be studied.
Disease Group: Melanoma and other malignant neoplasms of skin
Treatment Agent: Atezolizumab,Bevacizumab
Treatment Location: Only at MDACC
Sponsor: MD Anderson Cancer Center
IRB Review and Approval Date: 06/15/2017
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Melanoma and other malignant neoplasms of skin
Melanoma Medical Oncology
For general questions about clinical trials: